Literature DB >> 10457043

Functional gastroduodenal disorders.

N J Talley1, V Stanghellini, R C Heading, K L Koch, J R Malagelada, G N Tytgat.   

Abstract

While widely used in research, the 1991 Rome criteria for the gastroduodenal disorders, especially symptom subgroups in dyspepsia, remain contentious. After a comprehensive literature search, a consensus-based approach was applied, supplemented by input from international experts who reviewed the report. Three functional gastroduodenal disorders are defined. Functional dyspepsia is persistent or recurrent pain or discomfort centered in the upper abdomen; evidence of organic disease likely to explain the symptoms is absent, including at upper endoscopy. Discomfort refers to a subjective, negative feeling that may be characterized by or associated with a number of non-painful symptoms including upper abdominal fullness, early satiety, bloating, or nausea. A dyspepsia subgroup classification is proposed for research purposes, based on the predominant (most bothersome) symptom: (a) ulcer-like dyspepsia when pain (from mild to severe) is the predominant symptom, and (b) dysmotility-like dyspepsia when discomfort (not pain) is the predominant symptom. This classification is supported by recent evidence suggesting that predominant symptoms, but not symptom clusters, identify subgroups with distinct underlying pathophysiological disturbances and responses to treatment. Aerophagia is an unusual complaint characterized by air swallowing that is objectively observed and troublesome repetitive belching. Functional vomiting refers to frequent episodes of recurrent vomiting that is not self-induced nor medication induced, and occurs in the absence of eating disorders, major psychiatric diseases, abnormalities in the gut or central nervous system, or metabolic diseases that can explain the symptom. The current classification requires careful validation but the criteria should be of value in future research.

Entities:  

Mesh:

Year:  1999        PMID: 10457043      PMCID: PMC1766695          DOI: 10.1136/gut.45.2008.ii37

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  31 in total

1.  Empirical therapy versus diagnostic tests in gastroesophageal reflux disease: a medical decision analysis.

Authors:  A Sonnenberg; F Delcò; H B El-Serag
Journal:  Dig Dis Sci       Date:  1998-05       Impact factor: 3.199

2.  Dyspepsia and dyspepsia subgroups: a population-based study.

Authors:  N J Talley; A R Zinsmeister; C D Schleck; L J Melton
Journal:  Gastroenterology       Date:  1992-04       Impact factor: 22.682

3.  Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia.

Authors:  J M Hansen; P Bytzer; O B Schaffalitzky de Muckadell
Journal:  Am J Gastroenterol       Date:  1998-03       Impact factor: 10.864

Review 4.  Definitions of dyspepsia.

Authors:  R C Heading
Journal:  Scand J Gastroenterol Suppl       Date:  1991

Review 5.  Review article: functional dyspepsia--should treatment be targeted on disturbed physiology?

Authors:  N J Talley
Journal:  Aliment Pharmacol Ther       Date:  1995-04       Impact factor: 8.171

6.  What is behind dyspepsia?

Authors:  A G Klauser; W A Voderholzer; P A Knesewitsch; N E Schindlbeck; S A Müller-Lissner
Journal:  Dig Dis Sci       Date:  1993-01       Impact factor: 3.199

7.  Importance of reflux symptoms in functional dyspepsia.

Authors:  P K Small; M A Loudon; B Waldron; D Smith; F C Campbell
Journal:  Gut       Date:  1995-02       Impact factor: 23.059

8.  Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up.

Authors:  G M Forbes; M E Glaser; D J Cullen; J R Warren; K J Christiansen; B J Marshall; B J Collins
Journal:  Lancet       Date:  1994-01-29       Impact factor: 79.321

9.  Symptoms in gastro-oesophageal reflux disease.

Authors:  A G Klauser; N E Schindlbeck; S A Müller-Lissner
Journal:  Lancet       Date:  1990-01-27       Impact factor: 79.321

10.  Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia. A double-blind placebo-controlled evaluation of cisapride.

Authors:  R Jian; F Ducrot; A Ruskone; S Chaussade; J C Rambaud; R Modigliani; J D Rain; J J Bernier
Journal:  Dig Dis Sci       Date:  1989-05       Impact factor: 3.199

View more
  172 in total

Review 1.  Management of gastro-oesophageal reflux disease in general practice.

Authors:  J Dent; R Jones; P Kahrilas; N J Talley
Journal:  BMJ       Date:  2001-02-10

Review 2.  Treatment of Helicobacter pylori.

Authors:  A Harris
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

Review 3.  Natural history of dyspepsia.

Authors:  Lars Agréus
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

4.  Lump or split dyspepsia? A continuing controversy.

Authors:  N J Talley; S Thitiphuree
Journal:  Curr Gastroenterol Rep       Date:  2001-06

5.  Algorithmic approach to patients presenting with heartburn and epigastric pain refractory to empiric proton pump inhibitor therapy.

Authors:  Andrew K Roorda; Samuel N Marcus; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2011-04-22       Impact factor: 3.199

6.  DA-9601 for erosive gastritis: results of a double-blind placebo-controlled phase III clinical trial.

Authors:  Sang-Yong Seol; Myung-Hwan Kim; Jong-Sun Ryu; Myung-Gyu Choi; Dong-Wook Shin; Byoung-Ok Ahn
Journal:  World J Gastroenterol       Date:  2004-08-15       Impact factor: 5.742

7.  Functional Dyspepsia: A New Rome III Paradigm.

Authors:  Smita L S Halder; Nicholas J Talley
Journal:  Curr Treat Options Gastroenterol       Date:  2007-08

8.  Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients.

Authors:  W M Wong; B C Y Wong; W K Hung; Y K Yee; A W C Yip; M L Szeto; F M Y Fung; T S M Tong; K C Lai; W H C Hu; M F Yuen; S K Lam
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

9.  Homozygous 825T allele of the GNB3 protein influences the susceptibility of Japanese to dyspepsia.

Authors:  Tomomitsu Tahara; Tomiyasu Arisawa; Tomoyuki Shibata; Fangyu Wang; Masakatsu Nakamura; Mikijyu Sakata; Ichiro Hirata; Hiroshi Nakano
Journal:  Dig Dis Sci       Date:  2007-08-24       Impact factor: 3.199

10.  Itopride therapy for functional dyspepsia: a meta-analysis.

Authors:  Xuan Huang; Bin Lv; Shuo Zhang; Yi-Hong Fan; Li-Na Meng
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.